Physician profile
Jesus Rame
NPI 1417914953
$335,562.51
in general payments reported to CMS, 2019-2025
46 companies · $65K in 2025
The $65K reported for 2025 was more than what 95% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $10K · 2021: $4,176 · 2022: $109K · 2023: $94K · 2024: $43K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Honoraria: $36K · Travel and Lodging: $33K · Consulting Fee: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K · Food and Beverage: $11K · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,789.00 |
| Honoraria | $35,880.00 |
| Travel and Lodging | $33,189.28 |
| Consulting Fee | $17,486.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,456.25 |
| Food and Beverage | $11,096.19 |
| Education | $120.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $142,519.76 | 2022-2025 | Verquvo, Winrevair |
| E.R. Squibb & Sons, L.L.C. | $84,393.74 | 2021-2025 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $42,491.36 | 2023-2024 | Inpefa |
| Abbott Laboratories | $35,754.02 | 2019-2025 | Freestyle Libre Pro, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Fresenius USA Marketing, INC. | $10,750.28 | 2019-2023 | Novalung System |
| Bayer Healthcare Pharmaceuticals INC. | $6,904.07 | 2022-2025 | |
| Abiomed | $1,873.20 | 2019-2025 | Impella |
| Medtronic, INC. | $1,845.92 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $1,265.29 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Impulse Dynamics (USA) INC. | $868.90 | 2020-2025 | Optimizer, Optimizer |
| United Therapeutics Corporation | $861.44 | 2021-2025 | Tyvaso, Tyvaso, Remodulin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $742.70 | 2021-2025 | Jardiance |
| Baxter Healthcare | $718.18 | 2021-2025 | Floseal, Tisseel, Perclot |
| Daxor Corporation | $531.10 | 2023-2024 | Bva-100 |
| Astrazeneca Pharmaceuticals LP | $496.91 | 2021-2025 | Brilinta, Farxiga, Lokelma |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $343.12 | 2021-2022 | |
| Celgene Corporation | $300.00 | 2022 | |
| Ancora Heart, INC. | $285.68 | 2022 | |
| Medtronic Vascular, INC. | $274.12 | 2019-2020 | |
| Endotronix, INC. | $248.41 | 2022-2025 | Cordella Pulomonary Artery Pressure Sensor |
| Amgen INC. | $230.40 | 2020-2025 | Repatha |
| Pfizer INC. | $209.29 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $195.83 | 2020-2025 | |
| Cvrx, INC. | $192.37 | 2021-2024 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $191.31 | 2022-2024 | Lifevest |
| Novo Nordisk INC | $141.66 | 2021-2024 | Wegovy |
| Alnylam Pharmaceuticals INC. | $117.41 | 2020-2025 | Onpattro |
| Heartflow, INC. | $108.99 | 2025 | |
| Nuwellis, INC. | $90.33 | 2021-2022 | |
| Picard Medical INC. | $83.40 | 2023 | |
| Janssen Pharmaceuticals, INC | $75.85 | 2022-2024 | Xarelto |
| Philips North America LLC | $74.00 | 2022 | |
| One Lambda, INC. | $65.16 | 2025 | |
| Scpharmaceuticals INC. | $52.86 | 2024-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $45.20 | 2023 | Arcalyst |
| Atricure, INC. | $26.78 | 2023 | |
| Ge Healthcare | $25.27 | 2020 | |
| Daiichi Sankyo INC. | $24.51 | 2023 | Injectafer |
| Irhythm Technologies, INC. | $22.85 | 2021 | |
| Sandoz INC. | $22.18 | 2022 | |
| Bridgebio Pharma, INC. | $21.40 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $20.08 | 2024 | Nexletol |
| Kci USA, INC. | $19.66 | 2023 | Activ.A.C., V.A.C. Dermatac |
| Edwards Lifesciences Corporation | $18.85 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Akcea Therapeutics, INC. | $18.67 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Rame listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.